Is tazestat covered by medical insurance? What is the reimbursement ratio?

Tazemetostat is a targeted inhibitor of the EZH2 epigenetic enzyme. Its main indications include two types of tumors: one is EZH2-mutated or wild-type relapsed/refractory follicular lymphoma (FL; non-Hodgkin's disease) Golden lymphoma), especially for patients whose disease has not been controlled after at least two previous systemic treatments; second, metastatic or unresectable epithelioid sarcoma (ES; soft tissue sarcoma), which provides a new treatment option especially when effective treatments are lacking. The establishment of these indications has brought significant clinical benefits to patients who previously lacked effective treatment options.

Regarding the medical insurance situation, as of now, tazetostat, as the original drug, has only been on the market for a short time in mainland China and has not yet entered the national medical insurance catalog. The relevant reimbursement policies and proportions have not yet been clarified. Because it is still a new type of targeted drug, medical insurance access generally requires a long period of clinical data accumulation and expert consensus support. Before it is included in medical insurance, patients must pay for the treatment in full, and the financial burden is relatively heavy. Different provinces and cities also vary in whether they have set up temporary payment mechanisms for local medical insurance. Some patients may be able to reduce their burden through charity assistance or pharmaceutical company assistance projects.

At present, the price of this drug in China is still mainly imported from the original research, and the treatment cycle is long. Economic accessibility has become a major limitation for its promotion and application. At the same time, the drug is also expected to be included in the negotiations on the national medical insurance list, especially on the basis of clear molecular targets, and its precise treatment properties will be more likely to be recognized by medical insurance policies.

Before full coverage by medical insurance, the clinical use of tazerestat was more concentrated in high-risk patient groups with no alternative treatment options. If the threshold can be lowered through the medical insurance payment mechanism in the future, it is expected that its application scope in follicular lymphoma and epithelioid sarcoma will be further expanded. Combined with its molecular mechanism, tolerance and innovative attributes, this drug is expected to become an important part of precision therapy in my country's tumor treatment system, promoting tumor treatment from traditional chemotherapy to a new stage of epigenetic intervention.

Reference materials:https://www.tazverik.com/